The neutrophilic dermatoses are a group of disorders characterized by skin lesions for which histological examination reveals intense epidermal and/or dermal inflammatory infiltrates composed primarily of neutrophils without evidence of infection. The myelodysplastic syndromes consist of a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and inadequate blood cell production with a variable risk of transformation to acute leukemia. Rarely, histiocytoid Sweet's syndrome occurring in patients with myelodysplastic syndrome has been described. We present a case of a 66-year-old woman with a history of myelodysplastic syndrome who developed histiocytoid Sweet's syndrome. We also review the literature and characterize patients with myelodysplastic syndrome who have developed histiocytoid Sweet's syndrome. tum diutinum, neutrophilic dermatosis of the dorsal hand, neutrophilic eccrine hidradenitis [6] , pyoderma gangrenosum, and Sweet's syndrome (SS) [1] .
The myelodysplastic syndromes (MDS) consist of a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and inadequate blood cell production and a variable risk of transformation to acute leukemia. MDS may occur de novo or may arise years after exposure to potentially mutagenic therapy (i.e., chemotherapy, radiation exposure). The patients' inability to properly produce normal erythrocytes, mature granulocytes, and platelets, often results in an array of systemic consequences such as anemia, bleeding, and an increased risk of infection [7] .
Evidence from cancer databases suggests that there are approximately 10,000 new cases of MDS diagnosed annually in the United States [8] . MDS occurs most commonly in older adults with a median age at diagnosis of 65 years and a male predominance. Review of the literature reveals six cases of histiocytoid Sweet's syndrome with MDS [9] [10] [11] [12] [13] [14] . When Sweet's syndrome is present, it portends a poor prognosis in patients with MDS [12] . 
Case report
A 66-year-old woman presented to the dermatology clinic with a one-month history of a rash. The patient reported she was diagnosed with MDS via bone marrow biopsy one year prior; she was started on azacitidine and continued this therapy with minimal improvement. The patient was receiving blood transfusions for anemia and thrombocytopenia.
She had not received granulocyte colony-stimulating-factor (G-CSF) at any point during her treatment. is precipitated by the patient having received a dermatosisassociated medication, most notoriously G-CSF [4] . SS may also result from a hypersensitivity reaction to a bacterial or viral antigen [16] . It has been postulated that photosensitivity may also play a role in the pathogenesis of SS, although the mechanism is unknown [17] . Furthermore, an alteration in the gene encoding protein tyrosine phosphatase nonreceptor 6 appears to be involved in the pathogenesis of SS and other subsets of neutrophilic dermatoses [18] .
While the pathogenesis of MDS remains poorly understood, studies suggest that the cell of origin has acquired multiple mutations resulting in dysplasia and ineffective hematopoiesis [19] . Systemic corticosteroids are the mainstay of therapy for SS. Prednisone, at a dosage of 1 mg/kg/day, may be given as a single morning dose. Intravenous pulse administration of methylprednisone sodium succinate (up to 1000 mg/day) over 1 or more hours, daily for three to five days, may be utilized for patients whose condition is refractory to other therapies [4] . Other therapies include: clofazimine, colchicine, cyclosporine, dapsone, high-potency corticosteroids (such as clobetasol propionate 0.05%), indometacin, intralesional corticosteroids, Lugol's solution, and potassium iodide [4] . Metronidazole has been effective in patients whose dermatosis is related to inflammatory bowel disease [4] . Tumor necrosis factor (TNF) antagonists such as etanercept, infliximab, and thalidomide have been shown to be effective [4, 23] .
Conclusion
Histiocytoid Sweet's syndrome is a rare variant of SS, which was originally described by Robert Sweet and is sometimes associated with MDS. SS belongs to a group of conditions Legend: CR = Current Report; M = male; MDS-myelodysplastic syndrome; N/A-not available; W = woman;
